Veterinary Diagnostics, Medical Devices & Software, Water Testing
Strategic Profile
IDEXX achieved pivotal 2025 milestones with successful launches of IDEXX Cancer Dx for canine lymphoma and meaningful adoption of IDEXX inVue Dx, expanding the role of diagnostics in earlier disease detection. The company derives approximately 35% of revenue from outside the United States, demonstrating strong global diversification. IDEXX maintains highly profitable operations with a 61.7% gross margin and 65% return on equity over the past 12 months.
Cyborg Score Rationale
Q4 2025 revenue reached $1.09 billion (up 14% YoY), EPS rose 18% to $3.08, and the core companion animal segment grew 15% with instrument revenue surging 76%. For 2026, IDEXX expects revenue of $4.63–$4.72 billion with EPS of $14.29–$14.80, representing 9-13% growth. Headwinds include declining pet visit rates from lower-income owners, requiring managed expectations.
Top Insights
IDEXX Cancer Dx canine lymphoma launch and inVue Dx instrument adoption ahead of initial goals represent transformational innovation expanding early disease detection capabilities
January 2026 ImageVue DR50 Plus launch offers high-definition AI-powered diagnostics with 25% less radiation than previous model and seamless integration with existing software ecosystem
Leadership transition: Michael Erickson becomes CEO May 12, 2026, with Jonathan Mazelsky transitioning to Executive Chair then retiring post-2027 shareholder meeting
Company planning 5,500 new InVueDx system placements in 2026 (vs. 6,400 in 2025) to offset visit headwinds, targeting 4% price growth globally
Named Competitors
Revvity — Competitor in diagnostics and life sciences
Luminex — Multiplex molecular diagnostics and assay platforms
Randox — In vitro diagnostic solutions
Recent Developments
(February 2026) Q4 2025 earnings beat with $1.09B revenue (+14% YoY) and $3.08 EPS (+18%), setting 2026 guidance of $4.63-4.72B revenue
(January 2026) Launched ImageVue DR50 Plus veterinary imaging system with AI diagnostics and 25% reduced radiation exposure
(January 2026) Named Michael Erickson as next CEO effective May 12, 2026; current CEO Mazelsky transitions to Executive Chair
(January 2026) Expanded IDEXX Cancer Dx panel to include mast cell tumor testing for dogs
Open the full interactive IDEXX Laboratories, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.